Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor

Key facts

Where
Newmarket and Toronto, CanadaSee the 3 sites

Where in Canada

  • Southlake HealthNewmarket, CanadaNot yet recruiting
  • 200 Elizabeth StreetToronto, CanadaTaking people
  • Sunnybrook Health Sciences CenterToronto, CanadaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Health Network, Toronto
Trial code
NCT07447908
Record updated
6 July 2026
Original description
Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.Read full original descriptionShow less

Ted Rogers Understanding of Exacerbations in Heart Failure 2 (TRUE-HF2): Observational Study

Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.

Inclusion: broad age range (> 18 years of age); NT-proBNP > 400 or 1000 if in AF; Within 3 months post discharge from HF hospitalization/ HF ED visit/ HF rapid clinic visit with intensification of diuretic therapy; NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction; Literacy in English; Patient provided informed consent.

Exclusion: End stage renal disease requiring dialysis; Post heart transplant; Unable to perform a CPET based on the standard protocol; Living with LVAD; MRP deems patient unfit for the study.

ClinicalTrials.gov NCT07447908